Dr. Husseini K. Manji, a visionary scientist behind esketamine, discusses its groundbreaking development as a treatment for depression. He shares insights into targeting NMDA receptors and the rigorous clinical trials leading to FDA approval. The conversation highlights the challenges of introducing novel psychiatric drugs, including regulatory hurdles and insurance issues. Dr. Manji also addresses the broader implications for mental health treatment and the promising future of psychedelic medicine, emphasizing the need for equality in mental health care.